On September 11, 2023, the Teoresi Group has announced the acquisition of MediCon Ingegneria, an Italian company highly specialized in the research, design, development, and certification of medical devices.
Teoresi Group is expanding its engineering knowledge to offer even more comprehensive and advanced solutions in the Life Science sector, by incorporating MediCon Ingegneria’s highly specialized know-how in the field of chips and miniaturized electronic solutions, as well as of specific regulations and certifications within the medical technology industry.
Both Teoresi and MediCon Ingegneria possess solid engineering competencies, a strong inclination for experimentation in cutting-edge technologies, and a common objective: bringing innovation to a high-impact sector such as life sciences.
In recent years, Teoresi has increased its activities in the Med Tech sector with significant investments in innovation and research, undertaking projects in the field of oncological therapy. From its birth, MediCon Ingegneria has specialized in the realm of medical devices and has realized projects ranging from the development of life-saving extracorporeal circulation devices to wearables that monitor patients‘ biometric data.
Technological complementarity and a shared mission are thus at the foundation of this operation that will lead Teoresi Group to grow in the Life Sciences sector.
The acquisition of MediCon is part of Teoresi Group’s external growth strategy started in January 2023 with the acquisitions of HiFuture and BindingFuture. This third acquisition is part of the Group’s growth strategy and market diversification: by expanding its offerings and transferring expertise developed in other sectors such as automotive, railway, and aerospace to the life sciences, the Group aims to innovate Med Tech, a sector it has been investing in for several years and that perfectly reflects Teoresi’s commitment to improving people’s lives, who are both the protagonists and ultimate beneficiaries of research.
This too is „Engineering for human life.“ For more information, please read the press release.